Suppl. Figure S3 from Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non–Small Cell Lung Cancer
Year: 2023
Type: other
Abstract: DFCI358 signaling with respect to mTOR; crizotinib+trametinib combination;RTK activation
Authors: Magda Bahcall, Mark M. Awad, Lynette M. Sholl, Frederick H. Wilson, Man Xu, Stephen Wang, Sangeetha Palakurthi, Jihyun Choi, Elena V. Ivanova, Giulia C. Leonardi, Bryan C. Ulrich, Cloud P. Paweletz, Paul T. Kirschmeier, Masayuki Watanabe, Hideo Baba, Mizuki Nishino, Rebecca J. Nagy, Richard B. Lanman, Marzia Capelletti, Emily S. Chambers, Amanda J. Redig, Paul A. VanderLaan, Daniel B. Costa, Yu Imamura, Pasi A. Jänne
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362405387